PURE Bioscience Reports 1-for-8 Reverse Stock Split

PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silverdihydrogen citrate (SDC) antimicrobial, today announced it has finalized areverse stock split. As previously announced in a news release dated August 1,2012, Pure Bioscience's stockholders approved a reverse stock split at theCompany's annual meeting of stockholders convened July 31, 2012. The Company'sBoard of Directors was authorized to proceed with an amendment to theCompany's Certificate of Incorporation to effect a reverse stock split anddetermine the effective date of the reverse split and the ratio of the splitwithin a range of no less than 1-for-4 or greater than 1-for-10.